<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vismodegib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vismodegib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vismodegib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="83366" href="/d/html/83366.html" rel="external">see "Vismodegib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F13765898"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Embryofetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Vismodegib can cause embryofetal death or severe birth defects when administered to a pregnant woman. Vismodegib is embryotoxic, fetotoxic, and teratogenic in animals. Teratogenic effects included severe midline defects, missing digits, and other irreversible malformations.</p>
<p style="text-indent:-2em;margin-left:2em;">Verify the pregnancy status of females of reproductive potential within 7 days prior to initiating vismodegib. Advise pregnant women of the potential risks to a fetus. Advise females of reproductive potential to use effective contraception during and after vismodegib. Advise males of the potential risk of vismodegib exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F13797019"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Erivedge</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871419"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Erivedge</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F13755425"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Hedgehog Pathway Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F13765936"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;">
<b>Note: </b>Verify pregnancy status within 7 days prior to therapy initiation (in patients who could become pregnant).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eab635ef-bd14-48d1-9b35-7e9ef3ebc0b7">Basal cell carcinoma, locally advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Basal cell carcinoma, locally advanced or metastatic:</b>
<b>Oral:</b> 150 mg once daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22670903','lexi-content-ref-28511673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22670903','lexi-content-ref-28511673'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i> If a dose is missed, resume dosing with the next scheduled dose.</p></div>
<div class="block dora drugH1Div" id="F50992072"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50989252"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block dot drugH1Div" id="F44479435"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Intolerable adverse reactions: Withhold vismodegib treatment for up to 8 weeks until improvement or resolution.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe cutaneous adverse reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms: Permanently discontinue vismodegib.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe or intolerable musculoskeletal adverse reactions: Withhold vismodegib treatment. Permanently discontinue vismodegib for recurrent severe or intolerable musculoskeletal adverse reactions.</p></div>
<div class="block adr drugH1Div" id="F13765912"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (64%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea (premenopausal women: 30%), weight loss (45%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia (11%), constipation (21%), decreased appetite (25%), diarrhea (29%), dysgeusia (55%), nausea (30%), vomiting (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (40%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (16%), muscle spasm (72%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (grade 3: 1%), hyponatremia (grade 3: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Azotemia (grade 3: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (grades 3/4: 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic injury</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms</p></div>
<div class="block coi drugH1Div" id="F13765909"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to vismodegib or any component of the formulation; pregnancy or females at risk of becoming pregnant; breastfeeding; male patients or female patients of childbearing potential who do not comply with the Erivedge Pregnancy Prevention Program; children and adolescents &lt;18 years of age.</p></div>
<div class="block war drugH1Div" id="F13765910"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Severe cutaneous adverse reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms, have been reported with vismodegib; may be life-threatening or fatal. Permanently discontinue vismodegib if severe cutaneous adverse reactions occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Musculoskeletal effects: Musculoskeletal adverse reactions, which may be accompanied by CPK elevations, have occurred with vismodegib (and with other medications that inhibit the Hedgehog pathway). Musculoskeletal and connective tissue adverse reactions occurred in a majority of patients; grade 3 events have been reported. The most frequent manifestations (all grades) were muscle spasms and arthralgias. Grade 3 or 4 CPK elevations occurred in a small percentage of patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatrics: Premature fusion of the epiphyses has been reported in pediatric patients exposed to vismodegib; the fusion progressed after vismodegib discontinuation in some cases. Vismodegib is not indicated for use in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Blood donations: Advise patients not to donate blood or blood products during vismodegib treatment and for at least 24 months after the last vismodegib dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Toxicity duration: In a study of vismodegib in patients with basal cell nevus syndrome (not an approved use), with discontinuation of vismodegib treatment, taste alteration and muscle cramps abated within 1 month, and scalp and body hair began to regrow within 3 months (Tang 2012).</p></div>
<div class="block foc drugH1Div" id="F13797020"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Erivedge: 150 mg</p></div>
<div class="block geq drugH1Div" id="F13765904"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322930"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Erivedge Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $572.94</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871420"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Erivedge: 150 mg</p></div>
<div class="block accres drugH1Div" id="F13765903"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">
<i>US:</i> Available at specialty pharmacies through the Erivedge Access Solutions program. Further information may be obtained from the manufacturer, Genentech, at 1-888-249-4918, or at www.ErivedgeAccessSolutions.com
                  </p>
<p style="text-indent:0em;margin-top:2em;">
<i>Canada:</i> Available through a controlled distribution program called Erivedge Pregnancy Prevention Program (EPPP). Registration with the program is required for participating prescribers and pharmacies. Patients must also be registered with the program and meet all necessary requirements to receive vismodegib. Consult product monograph for detailed information regarding program requirements. Further information may also be obtained at 1-888-748-8926.</p></div>
<div class="block adm drugH1Div" id="F13765940"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> May be administered with or without food. Swallow capsules whole; do not open or crush.</p></div>
<div class="block hazard drugH1Div" id="F49104603"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block meg drugH1Div" id="F13765901"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F203388s017lbl.pdf%23page%3D15&amp;token=k%2BKRkRIgfGpfRTIrO0DH2ovWh8qdgukZQSU8A7MioEV%2F8GTyR%2B%2FHmULp9oV19CLtRw9x3CqBboRkeRY6d4ISK33yB%2F1TJvErQN9hPFQWL9yHDAJ%2F33KmTJKuyTK1R%2FGl&amp;TOPIC_ID=17142" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203388s017lbl.pdf#page=15</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F13753724"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Basal cell carcinoma, metastatic or locally advanced:</b> Treatment (in adults) of metastatic basal cell carcinoma, or locally advanced basal cell carcinoma that has recurred following surgery or in patients who are not candidates for surgery and not candidates for radiation therapy.</p></div>
<div class="block mst drugH1Div" id="F13765899"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Vismodegib may be confused with glasdegib, sonidegib, vandetanib, vemurafenib, venetoclax</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13769106"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (minor), CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F13769104"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F52722738"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use; verify the patient is not pregnant within 7 days prior to treatment initiation in patients who could become pregnant. Patients who could become pregnant should use effective contraception during therapy and for 24 months after the last vismodegib dose.</p>
<p style="text-indent:0em;margin-top:2em;">Patients with partners who are or who could become pregnant should use condoms to prevent potential vismodegib exposure via semen during therapy and for 3 months after the last vismodegib dose; condoms should be used even after vasectomy. Semen should not be donated during treatment and for 3 months after the last dose of vismodegib.</p>
<p style="text-indent:0em;margin-top:2em;">Amenorrhea may occur; consider discussions on fertility preservation prior to therapy.</p></div>
<div class="block pri drugH1Div" id="F13765906"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action, and data from animal reproduction studies, in utero exposure to vismodegib may cause fetal harm. Vismodegib inhibits the Hedgehog pathway, which is critical to fetal development (Walterhouse 1999, Villavicencio 2000). Outcome data following inadvertent exposure to vismodegib during pregnancy are limited (Schnetzler 2022). Embryo-fetal death or severe birth defects may occur following exposure to vismodegib.</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for the diagnosis, treatment, and follow up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team) approach (ESMO [Peccatori 2013]). Vismodegib is not recommended for use in pregnant patients.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to vismodegib is ongoing. Persons exposed to vismodegib during pregnancy (directly or via seminal fluid) are encouraged to contact the Pregnancy Exposure Registry (1-888-835-2555).</p></div>
<div class="block brc drugH1Div" id="F13765908"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if vismodegib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for 24 months after the last vismodegib dose.</p></div>
<div class="block mop drugH1Div" id="F13765942"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Obtain CPK and creatinine levels at baseline and as clinically indicated (eg, if muscle symptoms are reported). Pregnancy test within 1 week prior to treatment initiation (in patients who could become pregnant). Monitor for signs/symptoms of cutaneous adverse reactions. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F13765924"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Basal cell cancer is associated with mutations in Hedgehog pathway components. Hedgehog regulates cell growth and differentiation in embryogenesis; while generally not active in adult tissue, Hedgehog mutations associated with basal cell cancer can activate the pathway resulting in unrestricted proliferation of skin basal cells. Vismodegib is a selective Hedgehog pathway inhibitor which binds to and inhibits Smoothened homologue (SMO), the transmembrane protein involved in Hedgehog signal transduction.</p></div>
<div class="block phk drugH1Div" id="F13765926"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 16.4 to 26.6 L</p>
<p style="text-indent:-2em;margin-left:4em;">Males: The average vismodegib concentration in semen was 6.5% of the average steady state plasma concentration on day 8</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99%; primarily to serum albumin and alpha<sub>1</sub> acid glycoprotein (AAG)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized by oxidation, glucuronidation, and pyridine ring cleavage, although &gt;98% of circulating components are as the parent drug</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 32%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life, elimination: Continuous daily dosing: ~4 days; Single dose: ~12 days</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~2.4 days (Graham 2011)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (82%); urine (~4%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23671727"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Erivedge</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference">
                  Erivedge (vismodegib) [prescribing information]. South San Francisco, CA: Genentech USA; March 2023.</div>
</li>
<li>
<div class="reference">
                  Erivedge (vismodegib) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21300760">
<a name="21300760"></a>Graham RA, Lum BL, Cheeti S, et al, “Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Solid Tumors: The Role of Alpha-1-Acid Glycoprotein Binding,” <i>Clin Cancer Res</i>, 2011, 17(8):2512-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/21300760/pubmed" id="21300760" target="_blank">21300760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-vi170. doi:10.1093/annonc/mdt199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32406291">
<a name="32406291"></a>Schnetzler G, Cuberos M, Bucher R, Stassen K, Mingrino R. Vismodegib (ERIVEDGE) pregnancy prevention programme: assessment of risk awareness. <i>J Dermatolog Treat</i>. 2022;33(1):466-472. doi:10.1080/09546634.2020.1770166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/32406291/pubmed" id="32406291" target="_blank">32406291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28511673">
<a name="28511673"></a>Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.<i> BMC Cancer.</i> 2017;17(1):332. doi: 10.1186/s12885-017-3286-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/28511673/pubmed" id="28511673" target="_blank">28511673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22670903">
<a name="22670903"></a>Sekulic A, Migden M, Oro AE, et al, “Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma,” <i>New Engl J Med</i>, 2012, 366(23):2171-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/22670903/pubmed" id="22670903" target="_blank">22670903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22670904">
<a name="22670904"></a>Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al, “Inhibiting the Hedgehog Pathway in Patients With the Basal-Cell Nevus Syndrome,” <i>New Engl J Med</i>, 2012, 366(23):2180-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/22670904/pubmed" id="22670904" target="_blank">22670904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11001584">
<a name="11001584"></a>Villavicencio EH, Walterhouse DO, Iannaccone PM. The sonic hedgehog-patched-gli pathway in human development and disease. <i>Am J Hum Genet</i>. 2000;67(5):1047-1054. doi:10.1016/S0002-9297(07)62934-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/11001584/pubmed" id="11001584" target="_blank">11001584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19726763">
<a name="19726763"></a>Von Hoff DD, LoRusso PM, Rudin CM, et al, “Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma,” <i>N Engl J Med</i>, 2009, 361(12):1164-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/19726763/pubmed" id="19726763" target="_blank">19726763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10064544">
<a name="10064544"></a>Walterhouse DO, Yoon JW, Iannaccone PM. Developmental pathways: sonic hedgehog-patched-GLI. <i>Environ Health Perspect</i>. 1999;107(3):167-171. doi:10.1289/ehp.99107167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vismodegib-drug-information/abstract-text/10064544/pubmed" id="10064544" target="_blank">10064544</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 17142 Version 161.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
